New Delhi : CURO Biosciences Private Limited, operating under the name ErlySign, has raised ₹16 crore in pre-Series A funding from investor Ashish Kacholia. The funding, facilitated by DerivativeSaint, a private equity and venture capital advisory firm, highlights the company’s focus on early cancer detection.
This development positions CURO Biosciences to contribute to the global diagnostics market, which is estimated to grow significantly, reaching $250 billion by 2030.
ErlySign’s innovation is a biomarker-based test kit capable of detecting oral precancerous conditions within just 15 minutes using a simple, non-invasive saliva sample. This groundbreaking solution addresses the limitations of current diagnostic methods, which are often painful, time-consuming, and expensive. ErlySign’s test kit promises a painless, affordable, and immediate alternative for early cancer detection, offering hope for timely intervention and improved survival rates.
Speaking about the progress, Shubhendra Singh Thakur, CEO and Founder of ErlySign, said, “Our initial studies revealed exceptional results, achieving 100 per cent specificity and 98.04 per cent sensitivity. The product, now in the final stages of clinical trials across multiple HCG sites, promises to be a game-changer. Beyond early detection, it will serve as a critical screening tool to eliminate unnecessary biopsies and invasive procedures.”
The funding will be instrumental in finalizing clinical trials, securing CDSCO approvals, and bringing ErlySign’s oral cancer detection kit to market. Additionally, it will support research and development, team expansion, and further patent filings.
Looking ahead, ErlySign has plans to leverage CRISPR miRNA-based testing technology to detect multiple types of cancer using the same saliva sample within 15–20 minutes. This cutting-edge technology has the potential to revolutionize cancer diagnostics by making early detection both accurate and accessible.
